Posted on 3/7/21
David Nevins Interviews Dr. Matthew Frieman, Associate Professor, University of Maryland School of Medicine
Dr. Frieman’s overall research goal is to create therapeutic interventions for viruses of public health concern by developing
Posted on 2/26/21
Byrna Technologies Reports Record Fourth Quarter And Full Fiscal 2020 Results
Byrna Technologies Inc. (OTCQB: BYRN) (CSE: BYRN) today announced results for its fiscal fourth quarter ended November 30, 2020.Fourth Quarter 2020 Compared to Fourth Quarter 2019: . . .
Posted on 2/26/21
Thermo Fisher Scientific Acquires Mesa Biotech
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has completed its previously announced acquisition of Mesa Biotech, Inc., a . . .
Posted on 2/26/21
Relivant to Acquire Silicon Therapeutics for $450 Million
Roivant Sciences today announced it has entered into a definitive agreement to acquire Silicon Therapeutics for $450 million in Roivant equity, with additional potential regulatory and . . .
Posted on 2/26/21
Mersana Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates . . .
Posted on 2/25/21
Biocytogen Acquires Antibody Discovery Platform
Biocytogen, a company dedicated to accelerating therapeutic antibody discovery, has announced the acquisition of a third Beacon Optofluidic system.
Posted on 2/25/21
Akebia Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Updates
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today reported financial results for . . .
Posted on 2/25/21
Medisafe Secures $30M in Series C
Medisafe, a leading digital therapeutics company creating digital drug companions, today announced that it has raised $30 million in Series C funding with investments led by . . .
Posted on 2/25/21
Moderna Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Updates
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the . . .
Posted on 2/25/21
Concert Pharmaceuticals Reports 2020 Financial Results and Provides Update on Clinical Programs
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the year ended December 31, 2020, and provided an update on its product pipeline.“As . . .
Posted on 2/25/21
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported . . .
Posted on 2/25/21
Acushnet Holdings Corp. Announces Fourth Quarter and Full Year 2020 Financial Results
FAIRHAVEN, Mass.--(BUSINESS WIRE)--Acushnet Holdings Corp. (NYSE:GOLF) published its fourth quarter and full year 2020 financial results on February 25, 2021. The results are available via the . . .
Posted on 2/25/21
Karuna Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides General Business Update
BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today . . .
Posted on 2/25/21
Albireo Reports Q4 and Year-End 2020 Financial Results and Business Update
BOSTON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today provided . . .
Posted on 2/25/21
Agios Reports Fourth Quarter and Full Year 2020 Financial Results
CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically . . .
Posted on 2/25/21
Radius Health Fourth Quarter and Full Year Results
BOSTON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today reported its financial results for the fourth quarter ended December 31, 2020 as . . .
Posted on 2/25/21
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results
CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both . . .
Posted on 2/25/21
Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update
CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for . . .
Posted on 2/25/21
Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update
CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive . . .
Posted on 2/25/21
Merck to Acquire Pandion Therapeutics
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pandion Therapeutics, Inc. (Nasdaq: PAND) today announced that the companies have entered into
Posted on 2/25/21
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
STAMFORD, Conn., Feb. 25, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe . . .
Posted on 2/25/21
Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies . . .
Posted on 2/25/21
Here's Why Bristol Myers Squibb Is Making A Mistake With Its Cash
Bristol Myers Squibb (NYSE:BMY) is generating plenty of cash flow and recently used $4 billion of its nest egg to pay down debt. In this video . . .
Posted on 2/24/21
Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with . . .
Posted on 2/24/21
Xilio Therapeutics Raises $95 Million in Series C
Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immunotherapies for patients with cancer, today announced the successful closing of a $95 million Series C financing.
Boston
